EMA Authorised: Axitinib Accord (axitinib) — Accord Healthcare S.L.U.

View source ↗

Summary

The EMA authorised a new marketing authorisation for axitinib under the brand Axitinib Accord by Accord Healthcare S.L.U. for renal cell carcinoma, with decisio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Axitinib Accord (axitinib)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Renal Cell. MAH: Accord Healthcare S.L.U.. Decision date: 08/09/2025